Cognitive

Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Unlike parent ACTH, Semax does not stimulate adrenal steroidogenesis. Registered as a drug in Russia since 1994 for ischemic stroke and cognitive impairment, its research focuses on BDNF/NGF upregulation, neuroprotection in ischemia models, and attention enhancement. Western evidence is largely preclinical; human data derives mostly from Russian-language clinical publications.